Drug Trial Radar · NCT02678689
A Safety, Tolerability, and Efficacy Study of BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease
Last checked: Nov 20, 2026Latest source record: Feb 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14
Actual
Start
Jan 22, 2016
Primary completion
Apr 20, 2022
Study completion Apr 20, 2022
Sponsor
- Lead sponsor
- BioMarin PharmaceuticalBioMarin (BMRN)
- Sponsor type
- Industry
- First posted
- Feb 10, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2 open-label, multicenter study will evaluate the safety, tolerability, and efficacy of BMN 190 intracerebroventricular (ICV) administration every other week (qow) for a period of 144 weeks, in patients with CLN2. The study is designed to assess disease progression in CLN2 patients treated with BMN 190 compared to natural history data from untreated historical controls.
Conditions
- Jansky-Bielschowsky Disease
- Batten Disease
- Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
- CLN2 Disease
- CLN2 Disorder
Interventions
BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1)Biological
Intracerebroventricular access deviceDevice
Surgical implantation of an MRI compatible ICV access device in the lateral ventricle of the right hemisphere is required for administration of study drug.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Motor Language (ML) Scale: Rate of Decline in the 0 to 6-point ML Score.Time frame: Baseline to Last assessment (Week 169)
- Probability of Unreversed 2-Point Decline in Motor-language (ML) Score or Score of 0Time frame: Baseline to Last assessment (Week 169)
- Probability of Decline of Unreversed Motor-language (ML) Score of 0Time frame: Baseline to Last assessment (Week 169)
- Rate of Decline in Individual Motor DomainsTime frame: Baseline to Last assessment (Week 169)
- Rate of Decline in Individual Language DomainsTime frame: Baseline to Last assessment (Week 169)
Locations
4 sites in 4 countries. Site status is shown where the registry gives one.
Nationwide Children's Hospital
Columbus, Ohio
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, Germany
Children's Hospital Bambino Gesù,IRCCS
Rome, Piazza, Italy
Great Ormond Street Childrens Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.